The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.
Voss
S D
SD
Weil-Hillman
G
G
Hank
J A
JA
Sosman
J A
JA
Sondel
P M
PM
D000818:Animals; D003602:Cytotoxicity, Immunologic; D004341:Drug Evaluation; D005544:Forecasting; D006649:Histocompatibility Antigens / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000502:physiology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D006649:Histocompatibility Antigens; D007376:Interleukin-2